(1R,2S,6R,11S,13S,14S)-14-hydroxy-4-[[(2S)-oxolan-2-yl]methyl]-12-oxa-4-azatetracyclo[7.5.0.02,6.011,13]tetradec-8-ene-3,5,10-trione | 864278-47-7

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 异吲哚及其衍生物
• 英文名称: (1R,2S,6R,11S,13S,14S)-14-hydroxy-4-[[(2S)-oxolan-2-yl]methyl]-12-oxa-4-azatetracyclo[7.5.0.02,6.011,13]tetradec-8-ene-3,5,10-trione
• CAS: 864278-47-7
• 化学式: C₁₇H₁₉NO₆
• 分子量: 333.341
• InChiKey: LLIHEGOBMOWRBR-NWPLGXAWSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  -1
• 重原子数：
  24
• 可旋转键数：
  2
• 环数：
  5.0
• sp3杂化的碳原子比例：
  0.71
• 拓扑面积：
  96.4
• 氢给体数：
  1
• 氢受体数：
  6

反应信息

• 作为反应物：
  描述：

  (1R,2S,6R,11S,13S,14S)-14-hydroxy-4-[[(2S)-oxolan-2-yl]methyl]-12-oxa-4-azatetracyclo[7.5.0.02,6.011,13]tetradec-8-ene-3,5,10-trione 在 platinum(IV) oxide 氢气 、 盐酸 作用下， 以 乙酸乙酯 、 乙醚 、 二氯甲烷 为溶剂， 反应 4.0h， 生成 (3aR,5aR,8R,9S,9aS,9bS)-8,9-dihydroxy-2-[[(2S)-oxolan-2-yl]methyl]-4,5,5a,7,8,9,9a,9b-octahydro-3aH-benzo[e]isoindole-1,3,6-trione
  参考文献：
  名称：

  Stereocontrolled Synthesis of a Complex Library via Elaboration of Angular Epoxyquinol Scaffolds

  摘要：

  We have accomplished the synthesis of a complex chemical library via elaboration of angular epoxyquinol scaffolds with distinct skeletal frameworks. The key strategy involves highly stereocontrolled [4 + 2] Diels-Alder cycloadditions of chiral, nonracemic epoxyquinol dienes to generate the scaffolds. Further scaffold diversification involves hydrogenation, epimerization, dehydration, and condensation of the carbonyl group with alkoxyamine and carbazate building blocks. Further elaboration of the scaffolds also provided new skeletal frameworks using hydroxyl-directed Diels-Alder cycloaddition and reductive N-N bond cleavage. The overall process afforded 244 highly complex and functionalized compounds. Preliminary biological screening of the library uncovered six compounds which showed significant inhibition of Hsp 72 induction.

  DOI：

  10.1021/jo050956y
• 作为产物：
  描述：

  [(1'R,2'S,6'S)-4'-bromospiro[1,3-dioxane-2,5'-7-oxabicyclo[4.1.0]hept-3-ene]-2'-yl]oxy-tert-butyl-dimethylsilane 在 tris(dibenzylideneacetone)dipalladium (0) 三苯胂 、 (antracen-9-yl)CH₂CH₂C(O)NH-resin 作用下， 以 甲苯 为溶剂， 反应 48.0h， 生成 (1R,2S,6R,11S,13S,14S)-14-hydroxy-4-[[(2S)-oxolan-2-yl]methyl]-12-oxa-4-azatetracyclo[7.5.0.02,6.011,13]tetradec-8-ene-3,5,10-trione
  参考文献：
  名称：

  Stereocontrolled Synthesis of a Complex Library via Elaboration of Angular Epoxyquinol Scaffolds

  摘要：

  We have accomplished the synthesis of a complex chemical library via elaboration of angular epoxyquinol scaffolds with distinct skeletal frameworks. The key strategy involves highly stereocontrolled [4 + 2] Diels-Alder cycloadditions of chiral, nonracemic epoxyquinol dienes to generate the scaffolds. Further scaffold diversification involves hydrogenation, epimerization, dehydration, and condensation of the carbonyl group with alkoxyamine and carbazate building blocks. Further elaboration of the scaffolds also provided new skeletal frameworks using hydroxyl-directed Diels-Alder cycloaddition and reductive N-N bond cleavage. The overall process afforded 244 highly complex and functionalized compounds. Preliminary biological screening of the library uncovered six compounds which showed significant inhibition of Hsp 72 induction.

  DOI：

  10.1021/jo050956y

文献信息

• MOLECULAR ACTIVATORS OF THE WNT/BETA-CATENIN PATHWAY
  申请人：Moon Randall T.

  公开号：US20120046242A1

  公开（公告）日：2012-02-23

  The present invention is directed toward a method of treating a subject for a condition mediated by aberrant Wnt/β-catenin signaling by selecting a subject with a condition mediated by aberrant Wnt/β-catenin signaling and administering to the selected subject a compound selected from the group consisting of those set forth in Table 1, Table 2, and a pharmaceutically acceptable salt thereof. A method of similarly modulating the Wnt/β-catenin pathway in a subject is also discussed.
• [EN] MOLECULAR INHIBITORS OF THE Wnt/ß-CATENIN PATHWAY<br/>[FR] INHIBITEURS MOLÉCULAIRES DE LA VOIE WNT/BÊTA-CATÉNINE
  申请人：UNIV WASHINGTON

  公开号：WO2010075286A1

  公开（公告）日：2010-07-01

  The present invention is directed toward a method of treating a subject for a condition mediated by aberrant Wnt/β-catenin signaling by selecting a subject with a condition mediated by aberrant Wnt/β-catenin signaling and administering to the selected subject a compound selected from the group consisting of those set forth in Table 1, Table 2, and a pharmaceutically acceptable salt thereof. A method of similarly modulating the Wnt/ β-catenin pathway in a subject is also discussed.